This
work describes the discovery of a bead-bound membrane-active
peptide (MAP), LBF127, that selectively binds fungal giant unilamellar
vesicles (GUVs) over mammalian GUVs. LBF127 was re-synthesized in
solution form and demonstrated to have antifungal activity with limited
hemolytic activity and cytotoxicity against mammalian cells. Through
systematic structure–activity relationship studies, including
N- and C-terminal truncation, alanine-walk, and d-amino acid
substitution, an optimized peptide, K-oLBF127, with higher potency,
less hemolytic activity, and cytotoxicity emerged. Compared to the
parent peptide, K-oLBF127 is shorter by three amino acids and has
a lysine at the N-terminus to confer an additional positive charge.
K-oLBF127 was found to have improved selectivity toward the fungal
membrane over mammalian membranes by 2-fold compared to LBF127. Further
characterizations revealed that, while K-oLBF127 exhibits a spectrum
of antifungal activity similar to that of the original peptide, it
has lower hemolytic activity and cytotoxicity against mammalian cells.
Mice infected with Cryptococcus neoformans and treated
with K-oLBF127 (16 mg/kg) for 48 h had significantly lower lung fungal
burden compared to untreated animals, consistent with K-oLBF127 being
active in vivo. Our study demonstrates the success
of the one-bead, one-compound high-throughput strategy and sequential
screening at identifying MAPs with strong antifungal activities.